Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs ConocoPhillips (COP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs ConocoPhillips — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $300.02 (market cap $39.89B), while ConocoPhillips trades at $110.49 (market cap $132.84B). The key difference: ConocoPhillips is far larger — about 3.3× Alnylam Pharmaceuticals, Inc.'s market cap, and ConocoPhillips pays a 3.08% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | COP | |
|---|---|---|
Market Cap | $39.89B | $132.84B |
Sector | Health | Energy |
52-Week High | $491.22 | $133.80 |
52-Week Low | $278.09 | $85.66 |
Enterprise Value | $38.15B | $149.81B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ConocoPhillips (COP) trades at $109.04, up 0.94% with a bullish technical signal despite mixed moving averages. The company maintains solid fundamentals with $58.94B revenue, 12.58% net margin, and consistent cash flow generation. Recent earnings show beats in Q3 2025 and Q1 2026, while analysts project strong Q2 2026 EPS of $2.85. The stock offers a dividend yield with recent $0.84 payout, supported by 74.51% buy ratings from coverage analysts.
COP presents a compelling value opportunity with P/E of 18.48 and EV/EBITDA of 6.08 below sector averages. The consensus price target of $137.14 implies 26% upside potential. Key risks include oil price volatility, geopolitical tensions affecting Middle East supply, and declining profit margins from 23.79% in 2022 to 13.55% in 2025. The upcoming Q2 earnings on August 6, 2026, will be crucial for validating growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →
